NASDAQ:RNA Avidity Biosciences (RNA) Stock Price, News & Analysis $40.46 -0.30 (-0.74%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$39.35▼$41.1850-Day Range$37.21▼$48.1452-Week Range$4.82▼$48.80Volume901,490 shsAverage Volume1.32 million shsMarket Capitalization$3.87 billionP/E RatioN/ADividend YieldN/APrice Target$55.86 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends Get Avidity Biosciences alerts: Email Address Avidity Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside38.1% Upside$55.86 Price TargetShort InterestBearish13.51% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.16Based on 4 Articles This WeekInsider TradingSelling Shares$14.68 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.96) to ($3.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.88 out of 5 starsMedical Sector571st out of 910 stocksPharmaceutical Preparations Industry263rd out of 426 stocks 4.5 Analyst's Opinion Consensus RatingAvidity Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAvidity Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Avidity Biosciences' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.51% of the outstanding shares of Avidity Biosciences have been sold short.Short Interest Ratio / Days to CoverAvidity Biosciences has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Avidity Biosciences has recently decreased by 0.23%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAvidity Biosciences does not currently pay a dividend.Dividend GrowthAvidity Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RNA. Previous Next 1.2 News and Social Media Coverage News SentimentAvidity Biosciences has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Avidity Biosciences this week, compared to 4 articles on an average week.Search InterestOnly 13 people have searched for RNA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Avidity Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -22% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avidity Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,679,680.00 in company stock.Percentage Held by InsidersOnly 3.68% of the stock of Avidity Biosciences is held by insiders.Read more about Avidity Biosciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Avidity Biosciences are expected to decrease in the coming year, from ($2.96) to ($3.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avidity Biosciences is -13.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avidity Biosciences is -13.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvidity Biosciences has a P/B Ratio of 5.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Avidity Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About Avidity Biosciences Stock (NASDAQ:RNA)Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.Read More RNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RNA Stock News HeadlinesAugust 22, 2024 | insidertrades.comAvidity Biosciences, Inc. (NASDAQ:RNA) Director Arthur A. Levin Sells 5,000 SharesAugust 19, 2024 | marketbeat.comThis Early-Stage Biotech Stock Is Up 400% — Should You Buy Now? (RNA)Avidity Biosciences' stock has performed incredibly well in 2024. Its Duchenne muscular dystrophy drug is showing strong results in trials.September 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… August 8, 2024 | insidertrades.comInsider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) CEO Sells 28,000 Shares of StockSeptember 5 at 1:15 PM | finance.yahoo.comAvidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness MonthSeptember 4 at 5:46 AM | msn.com2 Standout Biotech Stocks With 32% to 63% UpsideSeptember 2, 2024 | americanbankingnews.comBrokerages Set Avidity Biosciences, Inc. (NASDAQ:RNA) PT at $55.86August 31, 2024 | msn.comBarclays Initiates Coverage of Avidity Biosciences (RNA) with Overweight RecommendationSeptember 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… August 30, 2024 | americanbankingnews.comAvidity Biosciences (NASDAQ:RNA) Coverage Initiated at BarclaysAugust 28, 2024 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Addex Therapeutics (ADXN), Avidity Biosciences (RNA)August 28, 2024 | benzinga.comDeep Dive Into Avidity Biosciences Stock: Analyst Perspectives (10 Ratings)August 28, 2024 | prnewswire.comAvidity Biosciences to Participate in Upcoming Investor ConferencesAugust 28, 2024 | americanbankingnews.comAvidity Biosciences (NASDAQ:RNA) Price Target Cut to $53.00August 21, 2024 | prnewswire.comAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 20, 2024 | finance.yahoo.comAvidity, Kymera raise fresh funds; Walgreens partners with BARDAAugust 19, 2024 | msn.comThis Early-Stage Biotech Stock Is Up 400% - Should You Buy Now?August 19, 2024 | prnewswire.comAvidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional SharesSee More Headlines Receive RNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2024Today9/07/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RNA CUSIPN/A CIK1574111 Webwww.aviditybiosciences.com Phone858-401-7900FaxN/AEmployees190Year FoundedN/APrice Target and Rating Average Stock Price Target$55.86 High Stock Price Target$63.00 Low Stock Price Target$45.00 Potential Upside/Downside+38.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-212,220,000.00 Net Margins-2,381.82% Pretax Margin-2,381.82% Return on Equity-32.89% Return on Assets-28.85% Debt Debt-to-Equity RatioN/A Current Ratio15.78 Quick Ratio15.78 Sales & Book Value Annual Sales$10.60 million Price / Sales365.08 Cash FlowN/A Price / Cash FlowN/A Book Value$6.76 per share Price / Book5.99Miscellaneous Outstanding Shares95,637,000Free Float92,118,000Market Cap$3.87 billion OptionableOptionable Beta0.89 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Troy Edward Wilson J.D. (Age 55)Ph.D., Co-Founder & Independent Chairman Comp: $70kMs. Sarah Boyce (Age 52)President, CEO & Director Comp: $998.88kMr. Michael F. MacLean (Age 58)Chief Financial & Chief Business Officer Comp: $674.74kDr. W. Michael F. Flanagan Ph.D. (Age 61)Chief Scientific & Technical Officer Comp: $675.22kMs. Teresa McCarthy (Age 60)Chief Human Resources Officer Comp: $628.79kDr. Arthur A. Levin Ph.D. (Age 70)Distinguished Scientist, Strategic Leader & Director Comp: $304.69kMr. Eric B. Mosbrooker (Age 57)Chief Strategy Officer Comp: $45kProf. Mark E. Davis Ph.D.Scientific Founder, Member of Scientific Advisory Board and Member of Board of ManagersDr. Frank P. McCormick Ph.D. (Age 74)Scientific Founder & Member of Scientific Advisory Board Mr. Geoffrey M. Grande C.F.A.VP of Investor Relation & Corporate CommunicationMore ExecutivesKey CompetitorsPTC TherapeuticsNASDAQ:PTCTConstellation PharmaceuticalsNASDAQ:CNSTZogenixNASDAQ:ZGNXORIC PharmaceuticalsNASDAQ:ORICSolid BiosciencesNASDAQ:SLDBView All CompetitorsInsiders & InstitutionsArthur A LevinSold 5,000 sharesTotal: $225,950.00 ($45.19/share)Algert Global LLCBought 10,443 shares on 8/16/2024Ownership: 0.045%Creative PlanningBought 4,190 shares on 8/16/2024Ownership: 0.014%Quarry LPBought 1,700 shares on 8/16/2024Ownership: 0.002%The Manufacturers Life Insurance Company Bought 42,636 shares on 8/15/2024Ownership: 0.285%View All Insider TransactionsView All Institutional Transactions RNA Stock Analysis - Frequently Asked Questions How have RNA shares performed this year? Avidity Biosciences' stock was trading at $9.05 at the start of the year. Since then, RNA stock has increased by 347.1% and is now trading at $40.46. View the best growth stocks for 2024 here. How were Avidity Biosciences' earnings last quarter? Avidity Biosciences, Inc. (NASDAQ:RNA) announced its earnings results on Friday, August, 9th. The biotechnology company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.11. The biotechnology company had revenue of $2.05 million for the quarter, compared to the consensus estimate of $7.09 million. Avidity Biosciences had a negative net margin of 2,381.82% and a negative trailing twelve-month return on equity of 32.89%. When did Avidity Biosciences IPO? Avidity Biosciences (RNA) raised $150 million in an IPO on Friday, June 12th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO. Who are Avidity Biosciences' major shareholders? Avidity Biosciences' top institutional shareholders include Avoro Capital Advisors LLC (6.80%), Cowen AND Company LLC (5.36%), D. E. Shaw & Co. Inc. (0.77%) and Dimensional Fund Advisors LP (0.72%). Insiders that own company stock include Sarah Boyce, Michael F Maclean, W Michael Flanagan and Arthur A Levin. View institutional ownership trends. How do I buy shares of Avidity Biosciences? Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Avidity Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avidity Biosciences investors own include GTX (GTXI), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sarepta Therapeutics (SRPT), Avid Bioservices (CDMO), Dynavax Technologies (DVAX) and iBio (IBIO). This page (NASDAQ:RNA) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNA Stock Alerts